Coronary vasomotor function assessed by positron emission tomography

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 6, 2010, Pages 1213-1224

  Tamaki, Nagara ^a   Yoshinaga, Keiichiro ^a   Naya, Masanao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac PET; Coronary artery disease; Coronary vasomotor function; Myocardial blood flow

Indexed keywords

AMMONIA N 13; CARBON 11; COPPER 62; FLUORINE 18; RUBIDIUM 82; WATER O 15;

AGING; BLOOD VESSEL FUNCTION; CIGARETTE SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CORONARY RISK; DIABETES MELLITUS; HEART MUSCLE BLOOD FLOW; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW;

CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY VESSELS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTORS;

EID: 77954886498     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1311-x     Document Type: Review

References (110)

1. Society of Nuclear Medicine. Position statement: clinical use of cardiac positron emission tomography. Position paper of the Cardiovascular Council of the Society of Nuclear Medicine. J Nucl Med 1993;34:1385-8.
2. Schwaiger M, Ziegler S, Nekolla SG. PET/CT: challenge for nuclear cardiology. J Nucl Med 2005;46:1664-78.
3. Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med 2009;50:1076-87.
4. Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol 2009;54:1-15.
5. Tamaki N. PET perfusion tracer. In: Taillefer R, Tamaki N, editors. New radiotracers in cardiac imaging: principles and applications. Stanford, CT: Appleton & Lange; 1999. p. 213-27.
6. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;14:380-97.
7. Yoshinaga K, Chow BJ, Dekemp RA, et al. Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders. Curr Pharm Des 2005;11:903-32.
8. Yalamanchili P, Wexler E, Hayers M, Yu M, Bozek J, Kagan M, et al. Mechanism of uptake and retention of F-18-BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol 2007;14:782-8.
9. Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, et al. Evaluation of the novel myocardial perfusion positronemission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation 2009;119:2333-42.
10. Kuhle WG, Porenta G, Huang SC, et al. Quantification of regional myocardial blood flow using 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992;86:1004-17.
11. Muzik O, Beanlands RS, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91.
12. Bellina CR, Parodi O, Camici P, et al. Simultaneous in vitro and in vivo validation of nitrogen-13-ammonia for the assessment of regional myocardial blood flow. J Nucl Med 1990;31:1335-43.
13. Nienaber CA, Ratib O, Gambhir SS, et al. A quantitative index of regional blood flow in canine myocardium derived noninvasively with N-13 ammonia and dynamic positron emission tomography. J Am Coll Cardiol 1991;17:260-9.
14. Choi Y, Huang SC, Hawkins RA, et al. A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET. J Nucl Med 1993;34:488-97.
15. Tadamura E, Tamaki N, Yonekura Y, et al. Assessment of coronary vasodilator reserve by N-13 ammonia PET using the microsphere method and Patlak plot analysis. Ann Nucl Med 1995;9:109-18.
16. Bergmann SR, Fox KA, Rand AL, et al. Quantification of regional myocardial blood flow in vivo with H215O. Circulation 1984;70:724-33.
17. Walsh MN, Bergmann SR, Steele RL, et al. Delineation of impaired regional myocardial perfusion by positron emission tomography with H2 (15) O. Circulation 1988;78:612-20.
18. Iida H, Rhodes CG, de Silva R, et al. Myocardial tissue fractioncorrection for partial volume effects and measure of tissue viability. J Nucl Med 1991;32:2169-75.
19. Yamamoto Y, de Silva R, Rhodes CG, et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 15O-water and dynamic positron emission tomography. Circulation 1992;86:167-78.
20. Katoh C, Morita K, Shiga T, Kubo N, Nakada K, Tamaki N. Improvement of algorithm for quantification of regional myocardial blood flow using 15O-water with PET. J Nucl Med 2004;45:1908-16.
21. Ibrahim T, Nekolla SG, Schreiber K, Odaka K, Volz S, Mehilli J, et al. Assessment of coronary flow reserve: comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography. J Am Coll Cardiol 2002;39:864-70.
22. Schepis T, Gaemperli O, Treyer V, Valenta I, Burger C, Koepfli P, et al. Absolute quantification of myocardial blood flow with 13N-ammonia and 3-dimensional PET. J Nucl Med 2007;48:1783-9.
23. Herrero P, Markham J, Shelton ME, Bergmann SR. Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography. Circ Res 1992;70:496-507.
24. Herrero P, Markham J, Shelton ME, Weinheimer CJ, Bergmann SR. Noninvasive quantification of regional myocardial perfusion with rubidium-82 and positron emission tomography. Exploration of a mathematical model. Circulation 1990;82:1377-86.
25. Manabe O, Yoshinaga K, Katoh C, Naya M, deKemp RA, Tamaki N. Reproducibility of rest and hyperemic myocardial blood flow measurements with 82Rb dynamic PET. J Nucl Med 2009;50:68-71
26. Lautamaki R, George RT, Kitagawa K, Higuchi T, Merrill J, Voicu C, et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol Imaging 2009;36:576-86.
27. Fakhri GE, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud Y, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with 82Rb PET: comparison with 13N-ammonia PET. J Nucl Med 2009;50:1062-71.
28. deKemp RA, Ruddy TD, Hewitt T, Dalipaj MM, Beanlands RS. Detection of serial changes in absolute myocardial perfusion with 82Rb PET. J Nucl Med 2000;41:1426-35.
29. Scott NS, Le May MR, de Kemp R, et al. Evaluation of myocardial perfusion using rubidium-82 positron emission tomography after myocardial infarction in patients receiving primary stent implantation or thrombolytic therapy. Am J Cardiol 2001;88:886-9.
30. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 1996;37:1701-12.
31. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000;102:1233-8.
32. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation 1994;89:1013-22.
33. Merlet P, Mazoyer B, Hittinger L, et al. Assessment of coronary reserve in man: comparison between positron emission tomography with oxygen-15-labeled water and intracoronary Doppler technique. J Nucl Med 1993;34:1899-904.
34. Nagamachi S, Czernin J, Kim AS, Sum KT, Bottcher M, Phelps ME, et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med 1996;37:1626-31.
35. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 1999;40:1848-56.
36. Chareonthaitawee P, Christenson SD, Anderson JL, Kemp BJ, Hodge DO, Ritman EL, et al. Reproducibility of measurements of regional myocardial blood flow in a model of coronary artery disease: comparison of H215O and 13NH3 PET techniques. J Nucl Med 2006;47:1193-201.
37. Di Carli MF, Tobes MC, Mangner T, Levine AB, Muzik O, Chakroborty P, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 1997;336:1208-15.
38. Uren NG, Crake T, Tousoulis D, Seydoux C, Davies GJ, Maseri A. Impairment of the myocardial vasomotor response to cold pressor stress in collateral dependent myocardium. Heart 1997;78:61-7.
39. Furuyama H, Odagawa Y, Katoh C, Iwado Y, Yoshinaga K, Ito Y, et al. Assessment of coronary function in children with a history of Kawasaki disease using 15O-water positron emission tomography. Circulation 2002;105:2878-84.
40. Siegrist PT, Gaemperli O, Koepfli P, et al. Repeatability of cold pressor test-induced flow increase assessed with H (2) (15) O and PET. J Nucl Med 2006;47:1420-6.
41. Gould KL, Lipscom K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974;33:87-94.
42. Gould KL. Quantification of coronary artery stenosis in vivo. Circ Res 1985;57:341-53.
43. Demer LL, Gould KL, Goldstein RA, et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 1989;79:825-35.
44. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994;330:1782-8.
45. Beanlands R, Melon P, Muzik O. N-13 ammonia PET identifies reduced perfusion reserve in angiographically normal regions of patients with CAD. Circulation 1992;86(Suppl I): I-184.
46. Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 1995;91:1944-51.
47. Beanlands RS, Muzik O, Melon P, et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity. J Am Coll Cardiol 1995;26:1465-75.
48. Yoshinaga K, Katoh C, Noriyasu K, et al. Reduction of coronary flow reserve in areas with and without ischemia on stress perfusion imaging in patients with coronary artery disease: a study using oxygen 15-labeled water PET. J Nucl Cardiol 2003;10:275-83.
49. Van Tosh A, Garza D, Roberti R, et al. Serial myocardial perfusion imaging with dipyridamole and rubidium-82 to assess restenosis after angioplasty. J Nucl Med 1995;36:1553-60.
50. Stewart RE, Miller DD, Bowers TR, et al. PET perfusion and vasodilator function after angioplasty for acute myocardial infarction. J Nucl Med 1997;38:770-7.
51. Walsh MN, Geltman EM, Steele RL, et al. Augmented myocardial perfusion reserve after coronary angioplasty quantified by positron emission tomography with H2 (15) O. J Am Coll Cardiol 1990;15:119-27.
52. Kaufmann PA, Rimoldi OE, Gnecchi-Ruscone T, Luscher TF, Camici PG. Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses. Am J Physiol Heart Circ Physiol 2007;293: H2178-82.
53. Tsukamoto T, Morita K, Naya M, Katoh C, Inubushi M, Kuge Y, et al. Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging 2006;33:1150-6.
54. Czernin J, Muller P, Chan S, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88:62-9.
55. Uren NG, Camici PG, Melin JA, et al. Effect of aging on myocardial perfusion reserve. J Nucl Med 1995;36:2032-6.
56. Geltman EM, Henes CG, Senneff MJ, Sobel BE, Bergmann SR. Increased myocardial perfusion at rest and diminished perfusion reserve in patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1990;16:586-95.
57. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994;90:808-17.
58. Yokoyama I, Murakami T, Ohtake T, et al. Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med 1996;37:1937-42.
59. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 1996;94:3232-8.
60. Pitkanen OP, Nuutila P, Raitakari OT, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 1999;99:1678-84.
61. Pitkanen OP, Raitakari OT, Niinikoski H, et al. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 1996;28:1705-11.
62. Kaufmann PA, Gnecchi-Ruscone T, Schafers KP, Luscher TF, Camici PG. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol 2000;36:103-9.
63. Mellwig KP, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998;139:173-8.
64. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
65. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999;99:475-81.
66. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998;98:1291-6.
67. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
68. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
69. Yokoyama I, Momomura S, Ohtake T, et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation 1999;100:117-22.
70. Yokoyama I, Momomura S, Ohtake T, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997;30:1472-7.
71. Yokoyama I, Ohtake T, Momomura S, et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 1998;47:119-24.
72. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999;100:813-9.
73. Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995;91:635-40.
74. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993;42:1017-25.
75. Prior JO, Quinones MJ, Pampaloni MH, Facta AD, Schindler TH, Sayre JW, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005;111:2291-8.
76. Srinivasan M, Herreo P. McGill JB, Bennik J, Heere B, Lesniak D, et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2005;46:42-8.
77. Momose M, Abletshauser C, Nevere J, Nekolla SG, Schnell O, Standi E, et al. Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med 2002;29:1675-9.
78. Lautamaki R, Airaksinen KE, Seppanen M, et al. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes 2006;55:511-6.
79. Hattori N, Schnell O, Bengel FM, Rihl J, Nekolla SG, Drzezga AE, et al. Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. Eur J Nucl Med 2002;29:891-8.
80. Hesse B, Meyer C, Nielsen FS, Sato A, Hove JD, Holm S, et al. Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalization by acute angiotensin-converting enzyme inhibition. Eur J Nucl Med Mol Imaging 2004;31:362-8.
81. Bengel FM, Abletshouser C, Neverth J, et al. Effects of nateglinide on myocardial microvascular reactivity in type 2 diabetes mellitus; a randomized study using positron emission tomography. Diabet Med 2005;22:158-63.
82. Naoumova RP, Kindler H, Leccisotti L, et al. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized double blind, placebo-controlled study. J Am Coll Cardiol 2007;50:2051-8.
83. Czernin J, Sun K, Brunken R, Bottcher M, Phelps M, Schelbert H. Effect of acute and long-term smoking on myocardial blood flow and flow reserve. Circulation 1995;91:2891-7.
84. Campisi R, Czernin J, Schoder H, et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 1998;98:119-25.
85. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-4.
86. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-55.
87. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92:1094-100.
88. Iwado Y, Yoshinaga K, Furuyama H, et al. Decreased endothelium-dependent coronary vasomotion in healthy young smokers. Eur J Nucl Med Mol Imaging 2002;29:984-90.
89. Morita K, Tsukamoto T, Naya M, et al. Smoking cessation normalizes coronary endothelial vasomotor response assessed with 15O-water and PET in healthy young smokers. J Nucl Med 2006;47:1914-20.
90. Campisi R, Czernin J, Schoder H, Sayre JW, Schelbert HR. L-Arginine normalizes coronary vasomotion in long-term smokers. Circulation 1999;99:491-7.
91. Kozakova M, Palombo C, Pratali L, Pittella G, Galetta F, L'Abbate A. Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography. Hypertension 1997;29:551-9.
92. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993;87:86-93.
93. Gimelli A, Schneider-Eicke J, Neglia D, Sambuceti G, Giorgetti A, Bigalli G, et al. Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with degree of hypertrophy. J Am Coll Cardiol 1998;31:366-73
94. Laine H, Raitakari OT, Niinikoski H, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998;32:147-53.
95. Gistri R, Ebert AG, Palombo C, Marabotti C, Choudhury L, Camici PG. Effect of blood pressure lowering on coronary vasodilator reserve in arterial hypertension. Cardiovasc Drugs Ther 1994;8:169-71.
96. Schneider CA, Voth E, Moka D, et al. Improvement of myocardial blood flow to ischemic regions by angiotensinconverting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography. J Am Coll Cardiol 1999;34:1005-11.
97. Higuchi T, Abletshauser C, Nekolla SG, Schwaiger M, Bengel FM. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007;14:805-12.
98. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol 2002;40:703-9.
99. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, et al. Olmesartan, but not amlodipine, improves endotheliumdependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-9.
100. Gould KL, Nakagawa Y, Nakagawa K, Sdringola S, Hess MJ, Haynie M, et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Circulation 2000;101:1931-9.
101. Schindler TH, Facta AD, Prior JO, Campisi R, Inubushi M, Kreissl MC, et al. PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction. Eur J Nucl Med Mol Imaging 2006;33:1140-9.
102. Herzog B, Husmann L, Valenta I, Gaemperli O, Siergrist P, Tay FM, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography. J Am Coll Cardiol 2009;54:150-6.
103. Beanlands RS, Ziadi MC, Williams K. Quantitation of myocardial flow reserve using positron emission imaging. J Am Coll Cardiol 2009;54:157-9.
104. Tio RA, Dabeshlim AS, Slart R. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med 2009;50:214-9.
105. Neglia D, Michaelassi C, Trivieri MG. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.
106. Cecchi F, Olivotto I, Gistri R. Coronary microvascular dysfunction and prognostic in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
107. Schindler TH, Nitzsche EU, Schelbert HR, et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol 2005;45:1505-12.
108. Schindler TH, Nitzsche EU, Olschewski M, et al. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation 2004;110:1069-75.
109. Namdar M, Hany TF, Koepfli P, Siegrist PT, Burger C, Wyss CA, et al. Integrated PET/CT for the assessment of coronary artery disease: a feasibility study. J Nucl Med 2005;46:930-5.
110. Di Carli MF, Dorbala S, Hachamovitch R. Integrated cardiac PET-CT for the diagnosis and management of CAD. J Nucl Cardiol 2006;13:139-44.